ZAP Surgical Builds Market for its Novel ZAP-X Gyroscopic Radiosurgery Platform

ZAP Surgical Systems, Inc. announced 18 new system orders in 2020 for its recently commercialized ZAP-X Gyroscopic Radiosurgery platform.

February 12, 2021 — ZAP Surgical Systems, Inc. announced 18 new system orders in 2020 for its recently commercialized ZAP-X Gyroscopic Radiosurgery platform. The news marks an extraordinary increase in year-over-year order volume. Having recently launched a robust global infrastructure, orders originated from both hospital and free-standing centers in the United States, Germany, Italy, Switzerland, Japan and other countries.

“ZAP started 2020 with highly ambitious goals. By mid-year however, COVID dashed many hopes of achieving those original plans,” said Richard Rosene, executive vice president of global sales and marketing. “The market has obviously responded favorably to ZAP-X, and we’re incredibly grateful to have surpassed global pre-pandemic sales targets for the year. Given the COVID challenges faced by our customers in the hospital and private sectors, it’s a remarkable accomplishment.”

Stereotactic radiosurgery (SRS) is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors. Considered an alternative to surgery for many such indications, SRS is an outpatient procedure that often provides equivalent outcomes, yet requires no surgical incision, and little to no patient recovery period.

ZAP-X is also acclaimed for being the first and only vault-free SRS delivery system, thus typically eliminating the need for costly shielded radiation treatment rooms. Deploying a modern linear accelerator to produce radiation, ZAP-X also obviates the regulatory and heightened security requirements for providers to host live radioactive isotopes within their clinics.

“Historically, the associated costs and complexities of delivering SRS meant the vast majority of radiosurgery occurred primarily in the largest, most well-funded academic hospitals. We estimate this paradigm has left nearly 90% of potential SRS patient candidates without adequate access,” said John Adler, M.D., CEO of ZAP Surgical Systems, and professor emeritus of neurosurgery and radiation oncology at Stanford University. “ZAP-X has effectively broken down those barriers to now make it feasible to bring world-class SRS to more patients in more places.”

For more information: www.zapsurgical.com